Roche Diagnostics' AmpliChip™ CYP450 Test now Available From LabCorp®
News Nov 29, 2005
Laboratory Corporation of America® Holdings (LabCorp®) has announced the availability of Roche Diagnostics' Cytochrome AmpliChip™ P450 2D6/2C19 Genotyping and Phenotyping Assay as an enhancement to LabCorp's growing pharmacogenetics test menu.
Cleared by the U.S. Food and Drug Administration for diagnostic use, the assay utilizes DNA microarray technology to provide a method of identifying multiple genetic variants in two cytochrome P450 (CYP450) genes, CYP2D6 and CYP2C19.
These genes metabolize 40 to 45 percent of all prescription drugs, including antidepressants, pain relievers and cardiovascular agents.
Variants in these genes can cause individuals to metabolize certain medications slowly or quickly than normal, which can lead to serious side effects.
Identifying these variants can help healthcare providers select optimal drug doses for their patients and avoid potentially serious drug interactions.
"Because drugs do not work the same in all individuals, pharmacogenetic tests like those for CYP450 help physicians better understand gene-drug interactions and can make a significant difference in both quality and cost of patient care," said Myla Lai-Goldman, M.D., Executive Vice President, Chief Scientific Officer and Medical Director of LabCorp.
"Drugs and doses are typically adjusted, if needed, by trial and error, which may lead to a prolonged period before optimal therapy is achieved."
"Additionally, many drug reactions are due to inappropriate dosing, and unnecessarily high dosages cause unnecessary costs."
Bioethics Council Rules Heritable Genome Editing "Ethically Acceptable" In Certain CircumstancesNews
A leading UK bioethics advisory body has weighed in on the debate around human genetic modification, concluding that heritable genome editing – modifying the DNA of an egg, sperm or embryo with changes that will be passed on to future generations – could be ‘morally permissible’ in humans, provided key ethical tests are met.
Genetic Factors Leading to Rare Bone Fusion Disorder IdentifiedNews
Genome sequencing establishes multiple genes responsible for a rare condition that cause bone fusionREAD MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019